Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases

  1. Thomas Pietschmann
  1. Institute for Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research, Hannover, Germany, and German Centre for Infection Research, Hannover-Braunschweig, Germany
  1. Michaela Ulrike Gack, Editor
  1. Harvard Medical School

ABSTRACT

Chronic hepatitis C virus (HCV) infection causes severe liver disease and affects ca. 146 million individuals. Novel directly acting antivirals targeting HCV have revolutionized treatment. However, high costs limit access to therapy. Recently, several related drugs used in humans to treat allergies or as neuroleptics emerged as potent HCV cell entry inhibitors. Insights into their antiviral modes of action may increase opportunities for drug repurposing in hepatitis C and possibly other important human viral infections.

KEYWORDS

FOOTNOTES

    • Accepted manuscript posted online 2 November 2016.
  • Address correspondence to thomas.pietschmann{at}twincore.de.

  • Citation Pietschmann T. 2017. Clinically approved ion channel inhibitors close gates for hepatitis C virus and open doors for drug repurposing in infectious viral diseases. J Virol 91:e01914-16. https://doi.org/10.1128/JVI.01914-16.

| Table of Contents

This Article

  1. Accepted manuscript posted online 2 November 2016, doi: 10.1128/JVI.01914-16 J. Virol. vol. 91 no. 2 e01914-16
  1. » Abstract
  2. Figures
  3. Full Text
  4. PDF

Classifications

Article Usage Stats

  1. Article Usage Statistics

current issue

    August 2017, volume 91, issue 15
  1. Current Issue
  1. Alert me to new issues of JVI